Truist analyst Srikripa Devarakonda notes that AbbVie (ABBV) announced negative trial results for emraclidine in dual Phase 2 schizophrenia ...

This belief in the underlying strength of AbbVie’s portfolio and growth potential underpins Gould’s Buy rating on the stock. In another report released on November 6, Guggenheim also maintained a Buy ...

Now, Guggenheim predicts AbbVie’s shares could fall by as much as 3% on the news given the removal of those sales from ...

AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

Pharmaceutical company AbbVie (ABBV) is the latest stock in my portfolio to announce a higher dividend. Accompanying its third-quarter earnings report, AbbVie declared a 5.8% increase in its ...

On Tuesday, AbbVie Inc (ABBV) stock saw a modest uptick, ending the day at $201.68 which represents a slight increase of $1.21 or 0.60% from the prior close of $200.47. The stock opened at $200.49 and ...

On Friday, AbbVie Inc (ABBV) stock saw a decline, ending the day at $203.55 which represents a decrease of $-0.32 or -0.16% from the prior close of $203.87. The stock opened at $204.37 and touched a ...

AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of ...

In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against the other pharma stocks. Healthcare takes the concept of 'defensive' further than almost any industry ...

Several other research analysts have also commented on the stock. Sanford C. Bernstein started coverage on shares of AbbVie in a report on Thursday, October 17th. They issued a “market perform ...